Objective: We performed a retrospective review of clinical T1a renal cell carcinoma patients treated in our institution. The clinicopathological findings and patients' prognoses were analyzed according to tumor size, and risk factors for tumor recurrence were elucidated. Methods: A total of 140 cases of sporadic renal cell carcinoma with a diameter of 4 cm or less on computed tomography findings for preoperative evaluation were treated as clinical T1a. Patients underwent radical nephrectomy or nephron-sparing surgery, and were evaluated postoperatively every 3 -6 months to screen for metastatic disease. Patients' medical records were reviewed retrospectively and the status of each patient was assessed.
INTRODUCTION
The TNM classification for renal cell carcinoma (RCC) was first defined in 1974 (1) , and several revisions have since been made. Classification systems have used tumor size to stratify organ-confined RCC, and the 1997 revision considered a cutoff point of 7 cm to distinguish between T1 and T2 RCC (2) . The latest edition introduced a subdivision of T1 RCC (T1a vs. T1b) with a cutoff of 4 cm with the aim of providing easier identification of patients eligible for selective nephron-sparing surgery (NSS) (3) . Validation of this cutoff point for small organ-confined RCC has been reported (4) , and good clinical outcomes for T1a RCC were obtained (4, 5) .
On the other hand, several recent studies showed that distant metastases occasionally occur even in cases of small RCC. The reported rates of T1a RCC patients with distant metastasis ranged from 0.7 to 7.2% (6 -8) . Thompson et al. (7) reported that only 1 of 781 patients with tumors ,3 cm in diameter had synchronous metastasis at diagnosis. In contrast, Klatte et al. (8) reported 34 such cases among 609 patients (5.6%). In terms of recurrence-free survival of patients with small RCC, inconsistent results regarding whether tumor size does or does not affect tumor recurrence have been reported (7 -9) . The biology of small RCC remains unclear, and the clinical and pathological characteristics, as well as risk factors for metastasis and recurrence, have not been fully elucidated.
In this study, we performed a retrospective review of clinical T1a RCC patients treated in our institution. The clinicopathological findings and patients' prognoses were analyzed according to tumor size, and risk factors for tumor recurrence were elucidated.
PATIENTS AND METHODS

PATIENTS
From January 2000 to December 2008, 140 cases of sporadic RCC with a diameter of 4 cm or less in computed tomography (CT) or magnetic resonance imaging findings for preoperative evaluation were treated as clinical T1a RCC in our department. Cases of bilateral and/or multiple lesions or von Hippel -Lindau disease were excluded from this study. Preoperative evaluations, including blood test, chest and abdominal CT and bone scintigraphy, were performed. All patients underwent radical nephrectomy (RN) or NSS. Pathological stage, Fuhrman nuclear grade and histological subtype were assessed according to the Heidelberg classification (10) and the 2002 American Joint Committee on Cancer version of the TNM-staging system (3). Microvascular invasion had been assessed routinely in cases of RN or NSS upon diagnosis. To detect the vascular wall pathologically, Elastica van Gieson staining was performed in selected cases in which it was difficult to make the diagnosis of microvascular invasion. Patients were evaluated postoperatively by routine blood test and chest and abdominal CT every 3 -6 months to screen for metastatic disease. Bone scintigraphy and head CT were performed where indicated. Patients' medical records were reviewed and the status of each patient was assessed by their visits to the outpatient clinic.
STATISTICAL ANALYSIS
The data of surgery were used as the start of observation. Statistical analyses were performed using commercially available software (Prism, GraphPad Software). Comparisons between two groups were performed by unpaired t-test or Fisher's exact test. The probability and survival were estimated using the Kaplan -Meier method. Univariate analysis of differences between patient groups was performed with the log-rank test. Statistical significance was defined as P , 0.05.
RESULTS
PATIENT CHARACTERISTICS
RCC was confirmed histologically in all 140 patients. Their mean age, gender and clinical M stage by tumor diameter are presented in Table 1 . There were no significant differences in tumor size according to mean age or gender. Four cases of clinically metastatic disease at diagnosis were found. The rate of synchronous metastatic disease (M1) was 2.0% (2 of 100 cases) in cases with a tumor diameter of 30 mm or less and 2.9% (4 of 140 cases) in those with cT1a RCC. The correlation between metastatic disease and tumor size could not be defined because the sample size was too small.
PATHOLOGICAL FINDINGS BY TUMOR SIZE FOR CT1A RCC
The surgical and pathological characteristics of groups according to tumor diameter are presented in Table 2 . RN tended to be selected in cases with large tumors; however, this was not significant (P ¼ 0.0539). There were no correlations between tumor size and pathological stage, Fuhrman nuclear grade or histological type. The rate of cases with microvascular invasion on pathological findings increased according to tumor diameter (P ¼ 0.0031). There were no cases with pathological T3, Grade 3, non-clear cell type or microvascular invasion in the patients with a tumor diameter of 10 mm or less.
CLINICAL OUTCOMES
In terms of prognosis of the patients in this study, patient's status could be obtained for 105 cases with cT1N0M0. The mean postoperative follow-up period was 41.7 months (range 10 -120 months), and six patients showed recurrence of disease (5.7%). Pulmonary metastases alone were detected in four patients, and one patient showed bone metastasis alone. One patient died from RCC with recurrence of pulmonary and lymph node metastases. There were no cases of local recurrence. Recurrence-free rates in terms of surgical procedure and pathological stage are shown in Fig. 1 . The probability of non-recurrence at 5 years was 98.4% for the 638 Clinicopathological outcome of cT1a RCC patients undergoing RN and 97.2% for those treated with NSS (Fig. 1A) . There was no significant difference in recurrence-free rate between patients treated with RN and those treated with NSS. The probability of non-recurrence at 5 years was 98.9% for pT1a patients and 80.0% for pT3a patients (Fig. 1B) . Outcome data were available for only one pT3b patient, and no disease recurrence was seen in this case. There was no significant difference in the recurrencefree rate between pT1a and pT3a patients. Recurrence-free rates among the pT1a patients are shown in Fig. 2 . The probability of non-recurrence at 7 years was 85.7% for the patients with a tumor diameter of 30 mm or less and 48.3% for those with tumors measuring 31 mm or more in diameter ( Fig. 2A ). There were statistically significant differences in the recurrence-free rate between the patients with a tumor diameter of 31 mm or more and other patient groups. In terms of microvascular invasion on histological findings, the probability of non-recurrence at 7 years was 0% for patients with and 92.9% for those without microvascular invasion, respectively (Fig. 2B ). There was a statistically significant difference among these groups.
DISCUSSION
The recent widespread use of modern imaging modalities for early detection of RCC has led to an increase in detection of renal cancer in the early stages (11) . Good clinical outcomes after surgery for small RCC have been reported, and small RCC may have less aggressive biological potential. However, metastatic disease with small RCC, even tumor diameters of 3 cm or less, have been reported in several studies (6 -8,12 ). In our series, 2.0% of patients with a tumor diameter of 30 mm or less and 2.9% of those with cT1a RCC showed synchronous metastasis (M1). As the sample size was too small, it was not possible to compare these results with those of previous studies. The most important point to note was that some types of small RCC have aggressive metastatic potential from the early stages, and examinations to detect distant metastases should not be omitted before treatment. Pathological risk factors for synchronous distant metastasis in small RCC could not be elucidated in this study.
Several studies have indicated correlations between tumor size and malignant pathological features, such as pathological T3 and Fuhrman nuclear Grade 3 (6, 13, 14) . These reports showed tendencies for negative prognostic factors according to tumor size, especially above a tumor diameter of 3 cm. The reported rates of pT3 and Grade 3 in patients with tumor diameters of more than 3 cm were 12.1 -38 and 14.0 -25.5%, respectively. In the present study, there were no correlations between tumor size and pathological stage, Fuhrman nuclear grade and histological type, and the rates (100) of pT3 and Grade 3 in patients with tumors more than 30 mm in diameter were lower than those in previous reports. These differences can be explained by differences in patient selection and sample size. On the other hand, we reported that the rate of cases with microvascular invasion increased according to tumor diameter. To our knowledge, there have been no previous reports indicating the correlation between tumor size and microvascular invasion in small RCC, such as clinical T1a disease. Dall'Oglio et al. (15) reported that the rate of cases with microvascular invasion increased with increasing tumor size among patients with pathological T1 and T2 stage. Considering the biology of RCC, cancer cells may promote angiogenesis and microvascular invasion from the early stages of disease, and the risk of occurrence depends on volumetric tumor growth. There was no significant difference in recurrence-free rate between the patients undergoing RN and those treated with NSS in clinical T1a disease. This result was similar to that of a previous report (16) , and may support the recent accepted opinion that NSS is an established curative procedure for small RCC. In the present study, there was no significant difference in recurrence-free rate between patients with pT1a and those with pT3a. This was consistent with a recent report indicating that perinephric fat invasion was not a significant predictor of disease-free survival for tumors 7 cm or less in diameter (17) . Although only one patient died from cancer during our study period, statistical analysis could not be performed as the sample size was too small. However, perinephric fat invasion did not have a significant impact on cause-specific survival in patients with tumors measuring 7 cm or less in diameter in several previous studies (17) (18) (19) .
In cases of pathological T1a disease, the recurrence-free rate in patients with tumors 31 mm or more in diameter was significantly lower than in other patient groups. Considering the correlation between tumor size and microvascular invasion, this result reflected the importance of microvascular invasion as a prognostic risk factor for pT1 disease, and in fact the recurrence-free rate was significantly lower in the patients with than in those without microvascular invasion. Several recent reports noted the importance of microvascular invasion as a prognostic risk factor for localized RCC (12, 15, 20) . However, the correlation between tumor size and positive microvascular invasion was not demonstrated among the group with small RCC in these studies. In our series, the follow-up period of the patients was not so long, and there was a possibility of overemphasis of poor prognosis in patients with a tumor diameter of 31 mm or more (48.3% of the probability of non-recurrence at 7 years, Fig. 2) . Although a longer follow-up period is needed, the results of the present study demonstrated that tumors over 30 mm in diameter may have aggressive biological potential possibly due to microvascular invasion.
In conclusion, almost all cases of small RCC diagnosed as clinical T1a by preoperative imaging findings had good prognosis regardless of surgical procedure. However, screening examination for detecting distant metastases before surgery should not be omitted, and long-term follow-up is needed for these tumors, especially those over 30 mm in diameter with microvascular invasion on pathological findings.
